Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Science

HORIBA Medical launches new compact & versatile haematology analyser


Print article Print article
Refer this article Refer to a friend

2009-10-29 16:27:55 - New Pentra ES 60 open tube analyser ensures convenience & flexibility

Northampton, UK: HORIBA Medical has launched a new compact and highly versatile haematology analyser. The Pentra ES 60 five-part differential (DIFF) analyser expands HORIBA Medical’s open tube haematology analysis family, efficiently providing consistently high quality and accurate results for non-standard samples through proven HORIBA Medical expertise and technologies. Such patented HORIBA Medical technologies enable the Pentra ES 60 to deliver

micro-sampling capabilities and sample stability in excess of 48 hours.

As an open tube haematology analyser, the Pentra ES 60 is ideal for use where sample tubes and sample types may vary widely. Consequently, it can enable exceptionally flexible and convenient in vitro diagnostic testing of whole blood specimens. Covering 26 parameters (12 Complete Blood Count (CBC), 14 DIFF) and processing up to 60 samples an hour, the analyser provides extremely reliable results, including atypical lymphocytes and large immature cells.

The Pentra ES 60’s integrated Multi-Distribution Sampling System (MDSS) also enables micro-sampling (30 μL in CBC mode and 53 μL in CBC + DIFF), making the analyser ideal for paediatric or geriatric sample types, where only small sample volumes are available. Such small sample volume capabilities, with accompanying five-part DIFF, also makes the system highly suitable for research projects in areas such as stem cells, cancer, respiratory, pharmaceutical, clinical trials and sports science.

Ideal as a standalone analyser for small to medium sized laboratories, the Pentra ES 60 is a sleek and compact bench top system, designed to take up minimal workspace. The analyser’s Windows-based software makes it extremely simple to use, whilst also being adaptable to enable threshold adjustments for specific sample types. This flexibility is particularly useful in research-based environments. The simplicity of the analyser’s design also means there is no daily maintenance, just one automatic start up and shut down each day.

To ensure system security, the Pentra ES 60 can be set up with password protected access which also enables full audit trails for Quality Assurance purposes. With an external barcode reader the analyser guarantees 100% positive sample identification.


ABOUT HORIBA Medical:

www.horiba.com/uk/medical

Analysis Anywhere: HORIBA Medical (formerly known as HORIBA ABX) is a renowned specialist in the design and manufacture of automated in vitro diagnostic systems for haematology for over 25 years, and chemistry focused analytical solutions for over 10 years. From compact point of care (POC) to high throughput systems, HORIBA Medical has successfully developed an array of analysers and data management solutions to meet all needs, enabling analysis anywhere it is required.

Specialist bench top analysis: In addition to large NHS laboratories and Point of Care settings, HORIBA Medical systems are also found in many areas of industry requiring specialist analysis, including sports science, food and beverage, pharma and neutraceuticals, and clinical research. The company’s benchtop analysers, such as the ABX Pentra 60C+ for haematology and ABX Pentra 400 for chemistry analysis, are proving their worth in these environments due to their exceptional flexibility and ease of use.

Media enquiries: Alto Marketing Limited
Sarah Perceval
Tel +44 (0) 1489 557672
Email: sarahp@alto-marketing.com


Author:
Leigh Dilley
e-mail
Web: www.alto-marketing.com
Phone: 0441489557672

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.


Terms & Conditions | Privacy | About us | Contact PR-inside.com